Biggest changeThe recast income statement was derived as follows: (in 000s) Year ended September 30, 2021 Plus: Three months ended December 31, 2021 (Transition Period) Less: Three months ended December 31, 2020 Year ended December 31, 2021 Revenue $ 50,526 $ 24,618 $ 7,986 $ 67,158 Operating expenses 74,619 35,154 10,354 99,419 Loss from operations (24,093) (10,536) (2,368) (32,261) Net (loss) income (40,052) 772 (2,361) (36,919) 40 Table of Contents Results of Operations The following table presents our consolidated statements of operations for the periods indicated (in thousands, except percentages): Year Ended December 31, 2022 % of Revenue 2021 % of Revenue Revenue $ 146,120 100% $ 67,158 100% Operating expenses Cost of revenue(1) 123,845 85% 54,305 81% Software development(1) 5,545 4% 2,158 3% General and administrative(1) 62,510 43% 39,143 58% Selling and marketing(1) 7,749 5% 3,813 6% Total operating expenses 199,649 137% 99,419 148% Loss from operations (53,529) (32,261) Other non-operating income (expense) Change in fair value of warrant liabilities 24,225 (7,422) Realized loss from sale of short-term investments (2,162) — Recapitalization costs attributable to warrant liabilities — (1,731) Interest income, net 3,434 743 Total other non-operating income (expense) 25,497 (8,410) Loss before income taxes (28,032) (40,671) Income tax benefit (772) (3,752) Net loss $ (27,260) $ (36,919) Net loss per share, basic and diluted $ (0.38) $ (0.68) Weighted-average number of shares outstanding: 71,238,103 54,105,944 __________ (1) Prior period amounts have been updated to conform to current period presentation. 41 Table of Contents Comparison of the Year Ended December 31, 2022 and 2021 Revenue Disaggregated revenue by product line was as follows: Year Ended December 31, 2022 2021 % Change (in thousands, except percentages) Product Line(1): Short Distance $ 44,986 $ 26,507 70 % Jet and Other $ 29,355 $ 25,699 14 % MediMobility Organ Transport 71,779 14,952 380 % Total Revenue $ 146,120 $ 67,158 118 % __________ (1) Prior period amounts have been updated to conform to current period presentation.
Biggest changeThe trend and timing of our brand marketing expenses will depend in part on the timing of our expansion into new markets and other marketing campaigns. 41 T able of Contents Results of Operations The following table presents our consolidated statements of operations for the periods indicated (in thousands, except share and per share data): Year Ended December 31, 2023 % of Revenue 2022 % of Revenue Revenue $ 225,180 100% $ 146,120 100% Operating expenses Cost of revenue 183,058 81% 123,845 85% Software development 4,627 2% 5,545 4% General and administrative 95,174 42% 62,510 43% Selling and marketing 10,438 5% 7,749 5% Total operating expenses 293,297 130% 199,649 137% Loss from operations (68,117) (53,529) Other non-operating income (expense) Interest income, net 8,442 3,434 Change in fair value of warrant liabilities 2,125 24,225 Realized gain (loss) from sales of short-term investments 8 (2,162) Total other non-operating income 10,575 25,497 Loss before income taxes (57,542) (28,032) Income tax benefit (1,466) (772) Net loss $ (56,076) $ (27,260) Net loss per share, basic and diluted $ (0.76) $ (0.38) Weighted-average number of shares outstanding, basic and diluted 73,524,476 71,238,103 42 T able of Contents Comparison of the Year Ended December 31, 2023 and 2022 Revenue Disaggregated revenue by product line was as follows: Year Ended December 31, 2023 2022 % Change (in thousands, except percentages) Product Line: Short Distance $ 70,700 $ 44,986 57 % Jet and Other 27,876 29,355 (5) % MediMobility Organ Transport 126,604 71,779 76 % Total Revenue $ 225,180 $ 146,120 54 % For the years ended December 31, 2023 and 2022, revenue increased by $79.1 million or 54%, from $146.1 million in 2022 to $225.2 million in 2023.
Judgment in the assessment of qualitative factors of impairment include, among other factors: reviewing factors such as macroeconomic conditions, industry and market considerations, cost factors, entity-specific financial performance and other events, such as changes in the Company’s management, strategy and primary customer base, factors affecting the reporting unit.
Judgment in the assessment of qualitative factors of impairment include, among other factors: reviewing factors such as macroeconomic conditions, industry and market considerations, cost factors, entity-specific financial performance and other events, such as changes in the Company’s management, strategy and primary customer base, and factors affecting the reporting unit.
This technology stack was built with future growth in mind and is designed to allow our platform to be easily scaled to accommodate, among other things, rapid increases in flier volume, new routes, new operators, broader flight schedules, international expansion, next-generation verticraft and ancillary services (e.g., last/first-mile ground connections, trip cancellation insurance, baggage delivery) through our mobile apps, website and cloud-based tools.
This technology stack was built with future growth in mind and is designed to allow our platform to be easily scaled to accommodate, among other things, rapid increases in volume, new routes, new operators, broader flight schedules, international expansion, next-generation verticraft and ancillary services (e.g., last/first-mile ground connections, trip cancellation insurance, baggage delivery) through our mobile apps, website and cloud-based tools.
No EVA aircraft are currently certified by the FAA for commercial operations in the United States, and there is no assurance that research and development will result in government certified aircraft that are market-viable or commercially successful in a timely manner, or at all.
No EVA aircraft are currently certified by the FAA for commercial operations in the United States, and there is no assurance that OEM research and development will result in government certified aircraft that are market-viable or commercially successful in a timely manner, or at all.
The non-GAAP measures presented herein may not be comparable to similarly titled measures presented by other companies. These include Flight Profit, Flight Margin, and Adjusted EBITDA, which we define, explain the use of and reconcile to the nearest GAAP financial measure below.
The non-GAAP measure presented herein may not be comparable to similarly titled measures presented by other companies. These include Flight Profit, Flight Margin and Segment Adjusted EBITDA, which we define, explain the use of and reconcile to the nearest GAAP financial measure below.
Moreover, if fliers do not perceive our urban air mobility services to be reliable, safe, and cost-effective, or if we fail to offer new and relevant services and features on our platform, we may not be able to attract or retain fliers or increase their utilization of our platform.
If fliers do not perceive our urban air mobility services to be reliable, safe, and cost-effective, or if we fail to offer new and relevant services and features on our platform, we may not be able to attract or retain fliers or increase their utilization of our platform.
In evaluation the likelihood of utilizing our net deferred income tax assets, the significant factors that we consider include (1) strong earnings history exclusive of the loss that created the future deductible amount, coupled with evidence indicating loss is not an ongoing condition, (2) growth in the U.S. and global economies, (3) forecast of air transportation revenue trends, (4) impact of future taxable profits.
In evaluating the likelihood of utilizing our net deferred income tax assets, the significant factors that we consider include (1) strong earnings history exclusive of the loss that created the future deductible amount, coupled with evidence indicating loss is not an ongoing condition, (2) growth in the U.S. and global economies, (3) forecast of air transportation revenue trends, (4) impact of future taxable profits.
Our incremental borrowing rate is an estimate based on an analysis of publicly traded debt securities of companies with credit and financial profiles similar to our own. • Determining the lease term when a renewal option exists - some of the Company's leases include options to extend the lease, the Company uses judgement in determining whether a lease extension option would be exercised, this decision drives the ROU amortization period and the value of the ROU asset and the lease liability. • In embedded leases under certain CPAs with third-party aircraft operators, we use estimates in determining what portion of the minimum guarantee represents a lease component. 54 Table of Contents
Our incremental borrowing rate is an estimate based on an analysis of publicly traded debt securities of companies with credit and financial profiles similar to our own. • Determining the lease term when a renewal option exists - some of the Company's leases include options to extend the lease, the Company uses judgement in determining whether a lease extension option would be exercised, this decision drives the ROU amortization period and the value of the ROU asset and the lease liability. • In embedded leases under certain CPAs with third-party aircraft operators, we use estimates in determining what portion of the minimum guarantee represents a lease component.
This enables our operator partners to focus on training pilots, maintaining aircraft and flying, while we maintain the relationship with the client from booking through flight arrival. For flights offered for sale by-the-seat, Blade schedules flights based on demand analysis and takes the economic risk of aggregating fliers to optimize flight profitability, providing predictable margins for our operators.
This enables our operator partners to focus on training pilots, maintaining aircraft and flying, while we maintain the relationship with our customer from booking through flight arrival. For flights offered for sale by-the-seat, Blade schedules flights based on demand analysis and takes the economic risk of aggregating fliers to optimize flight profitability, providing predictable margins for our operators.
Blade operates in three key product lines across two segments (see Note 9 to the consolidated financial statements included herein for further information on reportable segments): Passenger segment • Short Distance – Consisting primarily of helicopter and amphibious seaplane flights in the United States, Canada and Europe between 10 and 100 miles in distance.
Blade operates in three key product lines across two segments (see Note 7 to the consolidated financial statements included herein for further information on reportable segments): Passenger segment • Short Distance – Consisting primarily of helicopter and amphibious seaplane flights in the United States, Canada and Europe between 10 and 100 miles in distance.
Cash (Used In) Provided by Financing Activities For the year ended December 31, 2022, net cash used in financing activities was $1.1 million, primarily reflecting $1.2 million cash paid for payroll tax payments made on behalf of employees in exchange for shares withheld by the Company (“net share settlement”), partially offset by $0.1 million proceeds from the exercise of stock options.
For the year ended December 31, 2022, net cash used in financing activities was $1.1 million, reflecting $1.2 million cash paid for payroll tax payments on behalf of employees in exchange for shares withheld by the Company (“net share settlement”), partially offset by $0.1 million of proceeds from the exercise of stock options.
Developments for 2022 Acquisitions On September 1, 2022, Blade acquired, through Blade Europe SAS, a wholly-owned French société par actions simplifiée subsidiary (“Blade Europe”), 100% of the share capital and voting rights of Héli Tickets France SAS (“Héli Tickets France”), a French société par actions simplifiée, which was then renamed “Blade France SAS” (“Blade France”) and of Helicopter Monaco SARL (“Helicopter Monaco”), a Monegasque société à responsabilité limitée, which was then renamed “Blade Monaco SARL” (“Blade Monaco”).
Blade Europe Acquisition On September 1, 2022, Blade acquired, through Blade Europe SAS, a wholly-owned French société par actions simplifiée subsidiary (“Blade Europe”), 100% of the share capital and voting rights of Héli Tickets France SAS (“Héli Tickets France”), a French société par actions simplifiée, which was then renamed “Blade France SAS” (“Blade France”) and of Helicopter Monaco SARL (“Helicopter Monaco”), a Monegasque société à responsabilité limitée, which was then renamed “Blade Monaco SARL” (“Blade Monaco”).
Critical Accounting Policies and Significant Judgments and Estimates This discussion and analysis of the Company’s financial condition and results of operations is based on the Company’s consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America, or U.S. GAAP.
Critical Accounting Estimates This discussion and analysis of the Company’s financial condition and results of operations is based on the Company’s consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America, or U.S. GAAP.
We also believe that excluding this non-cash ROU amortization expense will aid comparable to prior and future periods as we do not expect it to re-occur after the fourth quarter of 2022.
We also believe that excluding this non-cash ROU amortization expense will aid in comparing to prior and future periods as we do not expect it to re-occur after the fourth quarter of 2022.
Blade believes the exclusion of the ROU asset amortization from Flight Profit and Flight Margin is helpful as it better represents the Company's actual payable expenses in exchange for the flights served by the operators in the fourth quarter.
Blade believes the exclusion of the ROU asset amortization from Flight Profit and Flight Margin is helpful as it better represents the Company's actual payable expenses in 47 T able of Contents exchange for the flights served by the operators in the fourth quarter.
Large urban markets with existing heliport infrastructure should be able to accommodate EVA while other cities may need several years to permit and build such infrastructure.
Large urban markets with 39 T able of Contents existing heliport infrastructure should be able to accommodate EVA while other cities may need several years to permit and build such infrastructure.
Cost of Revenue Cost of revenue consists of flight costs paid to operators of aircraft and cars, landing fees and internal costs incurred in generating ground transportation revenue using the Company's owned cars. 39 Table of Contents Software Development Software development expenses consist primarily of staff costs and stock-based compensation costs. Software development costs are expensed as incurred.
Cost of Revenue Cost of revenue consists of flight costs paid to operators of aircraft and cars, landing fees, ROU asset amortization and internal costs incurred in generating organ ground transportation revenue using the Company's owned cars. Software Development Software development expenses consist primarily of staff costs and stock-based compensation costs. Software development costs are expensed as incurred.
See “—Capacity Purchase Agreements” within Note 13 to the consolidated financial statements for additional information and for information about future periods. Additionally, the Company has operating lease obligations related to real estate leases with expected annual minimum lease payments of $1.8 million and $1.3 million for the years ending December 31, 2023 and 2024, respectively.
See “—Capacity Purchase Agreements” within Note 11 to the consolidated financial statements for additional information and for information about future periods. Additionally, the Company has operating lease obligations related to real estate and vehicles with expected annual minimum lease payments of $1.9 million and $0.9 million for the years ending December 31, 2024 and 2025, respectively.
As of December 31, 2022 , we had commitments with various aircraft operators to purchase flights with the annual minimum guarantee of an aggregate value of $12.3 million and $18.0 million for the years ending December 31, 2023 and 2024, respectively. $1.4 million and $10.1 million, respectively of which may be cancelled by us immediately if a government authority enacts travel restrictions and $1.1 million and $9.0 million, respectively of which could be terminated by Blade for convenience upon 30 or 60 days’ notice with the annual minimum guarantee being pro-rated as of the termination date.
As of December 31, 2023 , we had commitments to purchase flights from various aircraft operators with aggregate minimum flight purchase guarantees of $14.0 million and $21.6 million for the years ending December 31, 2024 and 2025, respectively. $5.0 million and $13.3 million, respectively, of which may be cancelled by us immediately if a government authority enacts travel restrictions and $3.1 million and $0.0 million, respectively, of which could be terminated by Blade for convenience upon 30 or 60 days’ notice with the annual minimum guarantee being pro-rated as of the termination date.
In addition, as of December 31, 2022 and December 31, 2021, we had restricted cash of $1.1 million and $0.6 million, respectively. As of December 31, 2022 $150.7 million of short-term investments consisted of securities that are traded in highly liquid markets.
In addition, as of December 31, 2023 and December 31, 2022, we had restricted cash of $1.1 million and $3.1 million, respectively. As of December 31, 2023, $138.3 million of short-term investments consisted of securities that are traded in highly liquid markets.
During the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill.
During the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to earnings.
With $194.0 million of total liquid funds as of December 31, 2022, we anticipate that those will be sufficient to meet our current operational needs for at least the next 12 months from the date of filing this Annual Report.
With $166.1 million of total liquid funds as of December 31, 2023, we anticipate that we have sufficient funds to meet our current operational needs for at least the next 12 months from the date of filing this Annual Report.
Our long-term consumer-facing strategy is primarily focused on growth in by-the-seat products, and we believe that “Seats flown — all passenger flights” is an important indicator of our progress in executing on this growth strategy.
Our long-term consumer-facing strategy is 37 T able of Contents primarily focused on growth in by-the-seat products, and we believe that Seats Flown is an important indicator of our progress in executing on this growth strategy.
Some contracts with operators allow for pass-through of fuel price increases above a set threshold. We have historically passed through cost inflation to customers and most contracts with our MediMobility Organ Transport Customers automatically pass through any fuel surcharges, but there is no guarantee this will continue in the future.
We have historically passed through cost inflation to customers and most contracts with our MediMobility Organ Transport Customers automatically pass through any fuel surcharges, but there is no guarantee this will continue in the future.
We plan to continue making significant investments and implementing strategic initiatives in order to attract new fliers, such as flier acquisition campaigns and the launching of new scheduled routes. These investments and initiatives may not be effective in generating sales growth or profits.
Historically, we have made, and expect that we will need to continue to make, significant investments and implement strategic initiatives in order to attract new fliers, such as flier acquisition campaigns and the launching of new scheduled routes. These investments and initiatives may not be effective in generating sales growth or profits.
Our ability to successfully fulfill these requests with consistent pricing on the requested aircraft type, be it jet, turboprop or helicopter, is the primary metric by which MediMobility Organ Transport Customers evaluate our performance. We utilize the same aircraft and aircraft operators in our Passenger segment.
Our ability to successfully fulfill these requests with consistent pricing on the requested aircraft type, be it jet, turboprop or helicopter, is the primary metric by which Medical Customers evaluate our performance.
Performing a quantitative goodwill impairment test includes the determination of the fair value of a reporting unit and involves significant estimates and assumptions. These estimates and assumptions include, among others, revenue growth rates and operating margins used to calculate projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables.
These estimates and assumptions include, among others, revenue growth rates and operating margins used to calculate projected future cash flows, risk-adjusted discount rates, future economic and market conditions, and the determination of appropriate market comparables.
Year Ended December 31, 2022 Year Ended December 31, 2021 Passenger Medical Passenger Medical Segment net income (loss) $ (14,029) $ (2,930) $ (1,318) $ 542 Reconciling items: Depreciation and amortization 3,949 1,488 622 430 Stock-based compensation 1,227 269 2,009 146 Legal and regulatory advocacy fees(1) 1,874 — — — Contingent consideration compensation (earn-out)(2) — 6,289 — — Non-cash timing of ROU asset amortization(3) 612 — — — Segment Adjusted EBITDA $ (6,367) $ 5,116 $ 1,313 $ 1,118 __________ (1) Represents certain legal and regulatory advocacy fees for specific matters (the proposed flight volume restrictions at East Hampton Airport, potential operational restrictions on large jet aircraft at Westchester Airport) that we do not consider representative of legal and regulatory advocacy costs that we will incur from time to time in the ordinary course of our business.
Year Ended December 31, 2023 Year Ended December 31, 2022 Passenger Medical Passenger Medical (in thousands) Segment loss $ (33,503) $ (1,388) $ (14,029) $ (2,930) Reconciling items: Depreciation and amortization 5,204 1,703 3,949 1,488 Stock-based compensation 1,497 705 1,227 269 Impairment of intangible assets 20,753 — — — Legal and regulatory advocacy fees(1) 686 — 1,874 — Executive severance costs 375 — — — Contingent consideration compensation (earn-out)(2) — 9,734 — 6,289 Non-cash timing of ROU asset amortization(3) — — 612 — Segment Adjusted EBITDA $ (4,988) $ 10,754 $ (6,367) $ 5,116 (1) Represents certain legal and regulatory advocacy fees for specific matters (primarily the proposed restrictions at East Hampton Airport and the potential operational restrictions on large jet aircraft at Westchester Airport) that we do not consider representative of legal and regulatory advocacy costs that we will incur from time to time in the ordinary course of our business.
Cash Provided by (Used In) Investing Activities For the year ended December 31, 2022, net cash provided by investing activities was $79.3 million, driven by $258.4 million of proceeds from the sale of other short-term investments, $98.0 million of proceeds from maturities of held-to-maturity investments, partially offset by $227.3 million in purchases of held-to-maturity securities, $48.1 million in consideration paid for the acquisition of Blade Europe, $0.7 million in purchases of other short-term investments, $0.7 million in purchases of property and equipment (leasehold improvements and vehicles) and $0.2 million additional investment in the joint venture in India.
For the year ended December 31, 2022, net cash provided by investing activities was $79.3 million, driven by $258.4 million of proceeds from the sales of other short-term investments, $98.0 million of proceeds from maturities of held-to-maturity investments, partially offset by $227.3 million in purchases of held-to-maturity investments, $48.1 million in consideration paid for the acquisition of Blade Europe, $0.7 million in purchases of other short-term investments, $0.7 million in purchases of property and equipment, consisting of leasehold improvements and vehicles, and $0.2 million additional investment in the joint venture in India. 50 T able of Contents Cash Used In Financing Activities For the year ended December 31, 2023, net cash used in financing activities was $0.1 million, reflecting $0.1 million cash paid for payroll tax payments on behalf of employees in exchange for shares withheld by the Company (“net share settlement”), partially offset by $0.1 million of proceeds from the exercise of stock options.
Jet and Other revenue has historically been stronger in the first and fourth quarter (Q1 and Q4) given that our by-the-seat jet service has historically operated only between November and April. Medical segment Historically, MediMobility Organ Transport demand has not been seasonal.
Jet and Other revenue has historically been stronger in the first and fourth quarter (Q1 and Q4) given that our by-the-seat jet service between New York and South Florida has historically operated only between November and April.
However, there is no guarantee that we will continue to be able to secure dedicated aircraft at favorable rates, particularly given significant increases in demand for private jet aircraft in the United States in recent years.
However, there is no guarantee that we will continue to be able to secure dedicated aircraft at favorable rates, particularly given significant increases in demand for private jet aircraft in the United States in recent years. Periods of increased demand for private jets have historically led to increased charter costs and more limited availability in the spot jet charter market.
This metric is not always directly correlated with revenue given the significant variability in the price we charge per seat flown across our various products and routes.
This metric is not always directly correlated with revenue given the significant variability in the price we charge per seat flown across our various products and routes. For products and routes sold by-the-seat, we fly significantly more passengers at a low price per seat; which is captured by Seats Flown.
Year Ended December 31, 2022 2021 (in thousands, except percentages) Net cash used in operating activities $ (37,130) $ (21,630) Net cash provided by / (used in) investing activities 79,340 (316,173) Net cash (used in) / provided by financing activities (1,084) 330,700 Effect of foreign exchange rate changes on cash balances 72 (9) Net increase (decrease) in cash and cash equivalents and restricted cash 41,198 (7,112) 51 Table of Contents Cash Used In Operating Activities For the year ended December 31, 2022, net cash used in operating activities was $37.1 million, primarily driven by a net loss of $27.3 million, $17 thousand cash used for working capital requirements and adjusted for non-cash items consisting of income from change in fair value of warrant liabilities of $24.2 million, stock-based compensation expense of $8.3 million, depreciation and amortization of $5.7 million, realized loss of $2.2 million from the sale of short-term investments, $1.1 million accretion of interest income on held-to-maturity securities and deferred tax benefit of $0.8 million.
For the year ended December 31, 2022, net cash used in operating activities was $37.1 million, primarily driven by a net loss of $27.3 million and $17.0 thousand cash used for working capital requirements, adjusted for non-cash items consisting of income from change in fair value of warrant liabilities of $24.2 million, stock-based compensation expense of $8.3 million, depreciation and amortization of $5.7 million, realized loss of $2.2 million from the sale of short-term investments, accretion of interest income on held-to-maturity securities of $1.1 million, and a deferred tax benefit of $0.8 million.
Liquidity Requirements As of December 31, 2022, the Company had net working capital of $191.5 million, zero debt, cash and cash equivalents of $43.3 million and short-term investments of $150.7 million. The Company had net losses of $27.3 million and $36.9 million for the years ended December 31, 2022 and 2021, respectively.
Liquidity Requirements As of December 31, 2023 , the Company had net working capital of $170.8 million, zero debt, cash and cash equivalents of $27.9 million and short-term investments of $138.3 million. The Company had net losses of $56.1 million and $27.3 million for the year ended December 31, 2023 and 2022, respectively.
We believe that Blade is well positioned to introduce EVA into commercial service, once available, for a number of reasons. In our Passenger segment, we believe our existing Short Distance routes will be compatible with EVA, which are initially expected to have a limited range, and our existing terminal space will accommodate EVA.
In our Passenger segment, we believe our existing Short Distance routes will be compatible with EVA, which are initially expected to have a limited range, and our existing terminal space will accommodate EVA.
Our Business Model Blade leverages an asset-light business model: we neither own nor operate aircraft. Pilots, maintenance, hangar, insurance, and fuel are all costs borne by our network of operators, which provide aircraft flight time to Blade at fixed hourly rates.
Our Business Model Blade leverages an asset-light business model: we primarily utilize aircraft that are owned and/or operated by third-parties on Blade’s behalf. In these arrangements, pilots, maintenance, hangar, insurance, and fuel are all costs borne by our network of operators, which provide aircraft flight time to Blade at fixed hourly rates.
The $17 thousand cash used for working capital requirements was primarily driven by an increase in accounts receivable of $5.3 million (attributable to rapid growth in MediMobility Organ Transport), an increase in prepaid expenses and other current assets of $5.3 million (driven by prepayments to operators in connection with new capacity purchase agreements) and an increase in other non-current assets of $0.7 million (driven by an office lease deposit).
The $17.0 thousand cash used for working capital requirements was primarily driven by an increase in accounts receivable of $5.3 million, due to the rapid growth in MediMobility Organ Transport, an increase in prepaid expenses and other current assets of $5.3 million, driven by prepayments to operators in connection with new capacity purchase agreements, and an increase in other non-current assets of $0.7 million driven by an office lease deposit; fully offset by an increase in accounts payable and accrued expenses of $9.9 million, driven by timing of accruing for the Trinity contingent consideration compensation payment and for the 2022 short term incentive plan, an increase in deferred revenue of $0.7 million (driven by client prepayments), and a $0.6 million increase in lease liabilities (attributable to new leases entered into in 2022).
Other non-operating income (expense) Year Ended December 31, 2022 2021 % Change (in thousands, except percentages) Change in fair value of warrant liabilities $ 24,225 $ (7,422) Realized loss from sale of short-term investments (2,162) — Recapitalization costs attributable to warrant liabilities — (1,731) Interest income, net 3,434 743 Total other non-operating income (expense) $ 25,497 $ (8,410) NM(1) __________ (1) Percentage not meaningful For the year ended December 31, 2022, other non-operating income consists of: (i) $24.2 million non-cash income due to fair value revaluation of warrant liabilities as the value of the warrant liabilities fluctuates with the warrants’ market price; (ii) a $2.2 million realized loss from sale of short-term investments; and (iii) $3.4 million interest income, net of interest expense.
For the year ended December 31, 2022, other non-operating income consists of: (i) $24.2 million non-cash income due to fair value revaluation of warrant liabilities as the value of the warrant liabilities fluctuates with the warrants’ market price; (ii) a $2.2 million realized loss from sale of short-term investments; and (iii) $3.4 million interest income, net of interest expense.
In these areas, our urban air mobility services can provide the most time savings for our fliers, and given the short distances involved, costs for our services can be comparable to luxury, private car services. In addition, EVA may be commercially viable sooner in these markets given that battery technology constraints may limit the range of early models.
In these areas, our urban air mobility services can provide the most time savings for our fliers, and given the short distances involved, costs for our services can be comparable to luxury, private car services.
We typically pre-negotiate fixed hourly rates and flight times with our aircraft operators, paying only for flights actually flown, creating a predictable and flexible cost structure. Blade will sometimes provide guaranteed flight commitments to our aircraft operators.
When utilizing third-party aircraft and/or aircraft operators, we typically pre-negotiate fixed hourly rates and flight times, paying only for flights actually flown, creating a predictable and flexible cost structure.
Year Ended December 31, 2022 2021 % Change Segment net loss(1) Passenger $ (14,029) $ (1,318) (964) % Medical (2,930) 542 NM(2) Total segment net loss $ (16,959) $ (776) (2,085) % Segment Adjusted EBITDA(1) Passenger $ (6,367) $ 1,313 NM(2) Medical 5,116 1,118 358 % Total segment Adjusted EBITDA $ (1,251) $ 2,431 NM(2) __________ (1) See section titled “Reconciliations of Non-GAAP Financial Measures” for more information and reconciliations to the most directly comparable GAAP financial measure.
Year Ended December 31, 2023 2022 % Change Segment loss Passenger $ (33,503) $ (14,029) 139 % Medical (1,388) (2,930) (53) % Total segment loss $ (34,891) $ (16,959) 106 % Segment Adjusted EBITDA(1) Passenger $ (4,988) $ (6,367) (22) % Medical 10,754 5,116 110 % Total segment Adjusted EBITDA $ 5,766 $ (1,251) NM(2) (1) See section titled “Reconciliations of Non-GAAP Financial Measures” for more information and reconciliations to the most directly comparable GAAP financial measure.
Key Components of the Company’s Results of Operations Revenue For Short Distance revenue, seats or monthly or annual flight passes are typically purchased using the Blade App and paid for principally via credit card transactions, wire, check, customer credit, and gift cards, with payments principally collected by the Company in advance of the performance of related services.
Medical segment Historically, seasonality in our MediMobility Organ Transport business has not been significant. 40 T able of Contents Key Components of the Company’s Results of Operations Revenue Short Distance products are typically purchased using the Blade App and paid for principally via credit card transactions, wire, check, customer credit, and gift cards, with payments principally collected by the Company in advance of the performance of related services.
Our asset-light model, coupled with our exclusive passenger terminal infrastructure, is designed to facilitate a seamless transition to Electric Vertical Aircraft (“EVA” or “eVTOL”), which is expected to enable lower cost air mobility to the public that is both quiet and emission-free.
Based in New York City, Blade's asset-light model, coupled with its exclusive passenger terminal infrastructure and proprietary technologies, is designed to facilitate a seamless transition from helicopters and fixed-wing aircraft to Electric Vertical Aircraft (“EVA” or “eVTOL”), enabling lower cost air mobility that is both quiet and emission-free.
Medical segment • MediMobility Organ Transport – Consisting of transportation of human organs for transplant and/or the medical teams supporting these services.
Medical segment • MediMobility Organ Transport – Consisting primarily of transportation of human organs for transplant and/or the medical teams supporting these services. Blade also offers additional services including donor logistics coordination and support evaluating potential donor organs .
In the interim, we purchase offsets to counteract the carbon emissions generated by our urban air mobility services. 37 Table of Contents Factors Affecting our Performance Ability to attract and retain fliers in our Short Distance product line Our success depends in part on our ability to cost-effectively attract new fliers, retain existing fliers and increase utilization of our services by current fliers.
Factors Affecting our Performance Ability to attract and retain fliers in our Short Distance product line Our success depends, in part, on our ability to cost-effectively attract new fliers, retain existing fliers, and increase utilization of our platform by existing fliers.
Medical segment For the year ended December 31, 2022 compared to the same period in 2021, Medical net income decreased by $3.5 million from $0.5 million in 2021 to $(2.9) million in 2022. Medical Adjusted EBITDA increased by $4.0 million or 358% from $1.1 in 2021 to $5.1 million in 2022.
Passenger Adjusted EBITDA increased by $1.4 million or 22% for the year ended December 31, 2023 from $(6.4) million in the same period of 2022 to $(5.0) million in 2023.
We define “Seats flown — all passenger flights” as the total number of seats purchased by paying passengers on all flights, whether sold by-the-seat or within a charter arrangement.
Seats Flown The following table reflects the key operating metric we use to evaluate the Passenger segment: Year Ended December 31, 2023 2022 Seats flown – all passenger flights 154,608 106,368 We define “Seats flown — all passenger flights” (Seats Flown) as the total number of seats purchased by paying passengers on all flights, whether sold by-the-seat or within a charter arrangement.
Impact of inflation to our business We generally pay a fixed hourly rate to our third-party operators, based on flight hours flown. These rates are susceptible to inflation and are typically renegotiated on a yearly basis, with the exception of certain aircraft utilized primarily for organ transportation, which can be on two to three year contracts.
Impact of inflation to our business We generally pay a fixed hourly rate to our third-party operators, based on flight hours flown. These rates are susceptible to inflation and are typically renegotiated on a yearly basis, though some multi-year contracts have fixed rate increases. Some contracts with operators allow for pass-through of fuel price increases above a set threshold.
For the years ended December 31, 2022 and 2021, cost of revenue increased by $69.5 million or 128%, from $54.3 million during 2021 to $123.8 million in 2022 driven by increased flight volume and an increase in the average price per trip.
Cost of Revenue Year Ended December 31, 2023 2022 % Change (in thousands, except percentages) Cost of revenue $ 183,058 $ 123,845 48 % Percentage of revenue 81 % 85 % For the year ended December 31, 2023 and 2022, cost of revenue increased by $59.2 million or 48%, from $123.8 million during 2022 to $183.1 million in 2023 driven by increased flight volume and an increase in the average price per trip.
Refer to the disaggregated revenue discussion above under “—Comparison of the Year Ended December 31, 2022 and 2021—Revenue” for more details.
Medical segment For the years ended December 31, 2023 and 2022, Medical revenue increased by $54.8 million or 76%, from $71.8 million in 2022 to $126.6 million in 2023. Refer to the disaggregated revenue discussion above under “ — Comparison of the Year Ended December 31, 2023 and 2022—Revenue” for more details.
Passenger revenue increased by $22.1 million attributable to $18.5 million increase in Short Distance and $3.7 million increase in Jet and Other. Refer to the disaggregated revenue discussion above under “—Comparison of the Year Ended December 31, 2022 and 2021—Revenue” for more details.
Refer to the disaggregated revenue discussion above under “—Comparison of the Year Ended December 31, 2023 and 2022—Revenue” for more details. Passenger Flight Profit increased by $8.1 million or 72% for the year ended December 31, 2023, from $11.3 million in the same period of 2022 to $19.4 million in 2023.
(2) All other operating expenses refer to the total of software development, general and administrative and selling and marketing expense. 47 Table of Contents Segment Adjusted EBITDA Segment Adjusted EBITDA is defined as revenue less the following expenses: cost of revenue, software development, general and administrative and selling and marketing expenses associated with the segment, excluding non-cash items or certain transactions that management does not believe are reflective of our ongoing core operations (as shown in the table below).
Segment Adjusted EBITDA Segment Adjusted EBITDA is defined as segment income (loss) excluding non-cash items or certain transactions that are not indicative of ongoing Company operating performance and / or items that management does not believe are reflective of our ongoing core operations (as shown in the table below).
The following table shows a reconciliation of segment revenue to segment Flight Profit and segment net income (loss): Year Ended December 31, 2022 Year Ended December 31, 2021 Passenger Medical Passenger Medical Revenue $ 74,341 $ 71,779 $ 52,206 $ 14,952 Cost of revenue(1) (63,658) (60,187) (41,905) (12,400) Non-cash timing of ROU asset amortization 612 — — — Flight Profit 11,295 11,592 10,301 2,552 Flight Margin 15.2 % 16.1 % 19.7 % 17.1 % Flight Profit $ 11,295 $ 11,592 $ 10,301 $ 2,552 Reconciling items: Non-cash timing of ROU asset amortization (612) — — — All other operating expenses(2) (24,712) (14,522) (11,619) (2,010) Segment net income (loss) $ (14,029) $ (2,930) $ (1,318) $ 542 __________ (1) Prior period amounts have been updated to conform to current period presentation.
The following table shows a reconciliation of segment revenue to segment Flight Profit and segment loss: Year Ended December 31, 2023 Year Ended December 31, 2022 Passenger Medical Passenger Medical Revenue $ 98,576 $ 126,604 $ 74,341 $ 71,779 Cost of revenue (79,132) (103,926) (63,658) (60,187) Non-cash timing of ROU asset amortization — — 612 — Flight Profit $ 19,444 $ 22,678 $ 11,295 $ 11,592 Flight Margin 19.7 % 17.9 % 15.2 % 16.1 % Flight Profit $ 19,444 $ 22,678 $ 11,295 $ 11,592 Reconciling items: Non-cash timing of ROU asset amortization — — (612) — All other operating expenses(1) (52,947) (24,066) (24,712) (14,522) Segment loss $ (33,503) $ (1,388) $ (14,029) $ (2,930) (1) All other operating expenses refer to the total of software development, general and administrative and selling and marketing expense.
The initial term of the Aircraft Operator Agreement ends on December 31, 2032 and it will automatically renew for successive three year periods. Blade paid an aggregate cash purchase price for the Shares of Héli Tickets France and Helicopter Monaco of €47.8 million ($48.1 million).
The initial term of the Aircraft Operator Agreement ends on December 31, 2032 and it will automatically renew for successive three year periods.
Jet and Other revenue increased by $3.7 million or 14% from $25.7 million in 2021 to $29.4 million in 2022.
Jet and Other revenue decreased by $(1.5) million or (5)% from $29.4 million in 2022 to $27.9 million in 2023.
In addition to historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs.
In addition to historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. For important information regarding these forward-looking statements, please see the discussion above under the caption “Note Regarding Forward-Looking Statements.” 36 T able of Contents Overview Blade Air Mobility, Inc.
Blade believes that the non-GAAP measures discussed below, viewed in addition to and not in lieu of our reported U.S.
Reconciliations of Non-GAAP Financial Measures Certain non-GAAP measures included in this segment results of operations review have been derived from amounts calculated in accordance with GAAP but are not themselves GAAP measures. Blade believes that the non-GAAP measure discussed below, viewed in addition to and not in lieu of our reported U.S.
Based on our current liquidity, we believe that no additional capital will be needed to execute our current business plan over the next 12 months. Our longer term liquidity requirement will depend on many factors including the pace of our expansion into new markets, our ability to attract and retain customers for our existing products, capital expenditures and acquisitions.
Based on our current liquidity, we believe that no additional capital will be needed to execute our current business plan over the next 12 months.
For additional information about our segments, see Note 9 - “Segment and Geographic Information” in the notes to the consolidated financial statements of this Annual Report on Form 10-K. 44 Table of Contents Segment Revenue, Flight Profit and Flight Margin The following table presents our segment results for the years ended December 31, 2022 and December 31, 2021 (in thousands, except percentages): Year Ended December 31, 2022 2021 % Change Revenue Passenger $ 74,341 $ 52,206 42 % Medical 71,779 14,952 380 % Total revenue $ 146,120 $ 67,158 118 % Flight Profit(1) Passenger $ 11,295 $ 10,301 10 % Medical 11,592 2,552 354 % Total Flight Profit $ 22,887 $ 12,853 78 % Flight Margin(1) Passenger 15.2 % 19.7 % Medical 16.1 % 17.1 % Total Flight Margin 15.7 % 19.1 % __________ (1) See section titled “Reconciliation of Non-GAAP Financial Measures” for more information.
Segment Revenue, Segment Flight Profit and Segment Flight Margin The following table presents our segment results for the periods indicated (in thousands, except percentages): Year Ended December 31, 2023 2022 % Change Segment Revenue Passenger $ 98,576 $ 74,341 33 % Medical 126,604 71,779 76 % Total revenue $ 225,180 $ 146,120 54 % Segment Flight Profit(1) Passenger $ 19,444 $ 11,295 72 % Medical 22,678 11,592 96 % Total Flight Profit $ 42,122 $ 22,887 84 % Segment Flight Margin(1) Passenger 19.7 % 15.2 % Medical 17.9 % 16.1 % Total Flight Margin 18.7 % 15.7 % (1) See section titled “Reconciliations of Non-GAAP Financial Measures” for more information.
For the years ended December 31, 2022 and 2021, general and administrative expense increased by $23.4 million, or 60%, from $39.1 million in 2021 to $62.5 million in 2022.
Medical segment For the years ended December 31, 2023 and 2022, Medical net loss decreased by $1.5 million or 53%, from $(2.9) million in 2022 to $(1.4) million in 2023.
For the years ended December 31, 2022 and 2021, selling and marketing expense increased by $3.9 million, or 103%, from $3.8 million in 2021 to $7.7 million in 2022.
Selling and Marketing Year Ended December 31, 2023 2022 % Change (in thousands, except percentages) Selling and marketing $ 10,438 $ 7,749 35 % Percentage of revenue 5 % 5 % For the years ended December 31, 2023 and 2022, selling and marketing expense increased by $2.7 million, or 35%, from $7.7 million in 2022 to $10.4 million in 2023.
We earn interest income on our money market and short-term investments, the increase over the prior year period is attributable to higher interest rates in the current year period. Segment Results of Operations We operate our business as two reportable segments - Passenger and Medical.
We earn interest income on our money market and short-term investments. Segment Results of Operations We operate our business as two reportable segments - Passenger and Medical. For additional information about our segments, see Note 7 - “Segment and Geographic Information” in the notes to the consolidated financial statements of this Annual Report on Form 10-K.
For the year ended December 31, 2021, net cash used in investing activities was $316.2 million, driven by a $308.8 million purchase of other short-term investments, $23.1 million in consideration paid for the acquisition of Trinity, $12.4 million in consideration paid for the purchase of the exclusive rights to Helijet’s scheduled passenger routes in Canada and $0.5 million in purchases of property and equipment; partially offset by $28.5 million of proceeds from the sale of other short-term investments.
Cash Provided by Investing Activities For the year ended December 31, 2023, net cash provided by investing activities was $17.1 million, driven by $264.5 million of proceeds from maturities of held-to-maturity investments, $20.5 million of proceeds from the sales of other short-term investments, offset by $265.8 million in purchases of held-to-maturity investments, $2.1 million in purchases of property and equipment, consisting of leasehold improvements, furniture and fixtures for lounges used by the Passenger segment, and vehicles used by the Medical segment.
(2) Percentage not meaningful. Passenger segment For the year ended December 31, 2022 compared to the same period in 2021, Passenger net loss increased by $12.7 million from $(1.3) million in 2021 to $(14.0) million in 2022. Passenger Adjusted EBITDA decreased by $7.7 million from $1.3 million in 2021 to $(6.4) million in 2022.
(2) Percentage not meaningful. 46 T able of Contents Passenger segment For the years ended December 31, 2023 and 2022, Passenger net loss increased by $19.5 million or (139)%, from $(14.0) million in 2022 to $(33.5) million in 2023.
(3) We believe that excluding this non-cash ROU amortization expense will aid in comparing to prior and future periods as we do not expect it to re-occur after the fourth quarter of 2022. 48 Table of Contents Quarterly Disaggregated Revenue The following table sets forth our unaudited quarterly disaggregated revenue by product line for each of the eight quarters leading up to the period ended December 31, 2022.
(3) We believe that excluding this non-cash ROU asset amortization expense will aid in comparing to prior and future periods as we do not expect it to re-occur after the fourth quarter of 2022. 48 T able of Contents Liquidity and Capital Resources Sources of Liquidity As of December 31, 2023 and December 31, 2022 , we had total liquidity of $166.1 million and $192.1 million, respectively, consisting of cash and cash equivalents of $27.9 million and $41.3 million, respectively, and short-term investments of $138.3 million and $150.7 million, respectively.
Those increases were fully offset by: an increase in accounts payable and accrued expenses of $9.9 million driven by timing of accruing for the Trinity contingent consideration compensation payment and for the 2022 short term incentive plan; an increase in deferred revenue of $0.7 million (driven by client prepayments); and a $0.6 million increase in lease liabilities (attributable to new leases entered into in 2022).
The $6.7 million of cash used for working capital requirements was primarily driven by an increase in accounts receivable of $10.3 million (attributable to the rapid revenue growth in MediMobility Organ Transport), an increase in prepaid expenses and other current assets of $6.0 million, driven by prepayments made to operators in connection with capacity purchase agreements; partially offset by an increase in accounts payable and accrued expenses of $9.0 million, driven by the accrual for the Trinity contingent consideration compensation payment and for the 2023 short term incentive plan, and an increase in lease liabilities of $0.4 million.
The increase is attributable primarily to: (i) a $2.3 million increase in media spending, primarily attributable to the re-launched Blade Airport in June 2021; (ii) a $0.8 million increase in sales commissions attributable mainly to high MediMobility Organ Transport revenue growth from new clients; and (iii) a $0.5 million increase in staff costs due to increased headcount.
The increase is attributable primarily to: (i) a $1.4 million in European marketing expenses (which were included for only four months of the prior year), primarily sales commission; (ii) a $1.4 million increase in sales commissions attributable to MediMobility Organ Transport revenue growth from new clients; and (iii) a $1.0 million increase in US marketing staff costs.
Upon the conclusion of the measurement period, any subsequent adjustments are recorded to earnings. 53 Table of Contents Goodwill Assessment We review goodwill annually (in the fourth quarter) and whenever events or changes in circumstances indicate that goodwill might be impaired.
Goodwill Assessment We review goodwill annually (in the fourth quarter) and whenever events or changes in circumstances indicate that goodwill might be impaired. We make certain judgments and assumptions to determine our reporting units and in allocating shared assets and liabilities to determine the carrying values for each of our reporting units.
Growth in Short Distance revenue was driven by: the acquisition of Helijet’s passenger business in December 2021 (“Blade Canada”); increased US passenger volumes driven primarily by the reintroduction of our by-the-seat airport transfer products in June 2021; higher seat and charter prices, implemented during the 2022 period; and the acquisition of Blade Europe in September 2022.
Growth in Short Distance revenue was primarily driven by the acquisition of Blade Europe in September 2022, contributing growth of $19.8 million, increased volumes of Northeast helicopter charters for a $1.1 million increase, growth in our New York by-the-seat airport transfer products for $2.0 million, and growth in Canada for a $1.9 million increase.
Growth in Jet was driven primarily by an increase in the average price per jet charter trip and increased flight volumes on our seasonal by-the-seat jet service between New York and South Florida, partially offset by lower revenues from brand partners and ground transportation services.
Decrease in Jet was driven primarily by the discontinuation of our seasonal by-the-seat jet service between New York and South Florida in the fourth quarter ended December 2023 for a $1.7 million decrease, partially offset by increased brand partnership revenues for a $0.4 million increase.
For the years ended December 31, 2022 and 2021, revenue increased by $79.0 million or 118%, from $67.2 million in 2021 to $146.1 million in 2022. Short Distance revenue increased by $18.5 million or 70% from $26.5 million in 2021 to $45.0 million in 2022.
Passenger segment For the years ended December 31, 2023 and 2022, Passenger revenue increased by $24.2 million or 33%, from $74.3 million in 2022 to $98.6 million in 2023. The increase was attributable to a $25.7 million increase in Short Distance and a decrease of $1.5 45 T able of Contents million in Jet and Other.
Recent increased demand for private jets has led to increased charter costs and more limited availability in the spot jet charter market, but has not limited our ability to maintain or increase our access to dedicated jet aircraft at fixed prices.
Although this has not limited our ability to maintain or increase our access to dedicated jet aircraft at fixed prices in recent periods, jet charter, which makes up the majority of our Jet and Other business line, is highly competitive and volumes and pricing have historically been significantly influenced by overall market supply and demand.
General and Administrative General and administrative expenses principally include staff costs including stock-based compensation, depreciation and amortization, directors and officers insurance costs, professional fees, credit card processing fees and establishment costs. We expect that general and administrative expenses will increase for the foreseeable future as we expand our service offerings to additional cities and increase flight volumes on existing routes.
General and Administrative General and administrative expenses principally include staff costs including stock-based compensation, depreciation and amortization, impairment of intangible assets, directors and officers insurance costs, professional fees, credit card processing fees and establishment costs. Selling and Marketing Selling and marketing expenses consist primarily of advertising costs, staff costs including stock-based compensation, marketing expenses, sales commissions and promotion costs.
For products and routes sold by-the-seat, we fly significantly more passengers at a low price per seat; growth in these areas is captured by “Seats flown — all passenger flights,” but has less impact on revenue, which is heavily influenced by the Jet and Other product 35 Table of Contents lines where we typically fly fewer passengers over long distances at a high price.
Passenger revenue is heavily influenced by the Jet and Other product lines where we typically fly fewer passengers over long distances at a high price. We believe the Seats Flown metric is useful to investors in understanding the overall scale of our Passenger segment and trends in the number of passengers paying to use our service.
Medical segment For the year ended December 31, 2022 compared to the same period in 2021, Medical revenue increased by $56.8 million or 380%, Medical Flight Profit increased by $9.0 million or 354%, with Flight Margins at 16.1% versus 17.1%. Medical revenue increased by $56.8 million, with the increase attributable to MediMobility Organ Transport.
Medical Flight Margin increased from 16.1% in the year ended December 31, 2022 to 17.9% in the same period in 2023.
See Note 7 “Right-of-Use Asset and Operating Lease Liability” to the consolidated financial statements for additional information and for information about future periods. We expect to incur net losses in the short term, as we continue to execute our strategic initiatives.
See Note 5 “Right-of-Use Asset and Operating Lease Liability” to the consolidated financial statements for additional information and for information about future periods. We have non-cancellable commitments which primarily relate to cloud services and other items in the ordinary course of business. The amounts are determined based on the non-cancellable quantities to which we are contractually obligated.
General and Administrative Year Ended December 31, 2022 2021 % Change (in thousands, except percentages) General and administrative(1) $ 62,510 $ 39,143 60 % Percentage of revenue 43 % 58 % __________ (1) Prior period amounts have been updated to conform to current period presentation.
General and Administrative Year Ended December 31, 2023 2022 % Change (in thousands, except percentages) General and administrative $ 95,174 $ 62,510 52 % Percentage of revenue 42 % 43 % For the years ended December 31, 2023 and 2022, general and administrative expense increased by $32.7 million, or 52%, from $62.5 million in 2022 to $95.2 million in 2023.
However, manufacturers, individual operators that will 38 Table of Contents purchase EVA, and pilots must receive requisite approvals from federal transportation authorities before EVA can fly passengers.
However, EVA involves a complex set of technologies, which we rely on original equipment manufacturers (“OEMs”) to develop and our third-party aircraft operators to adopt. However, before EVA can fly passengers or cargo, OEMs must receive requisite approvals from federal transportation authorities.
Passenger segment For the year ended December 31, 2022 compared to the same period in 2021, Passenger revenue increased by $22.1 million or 42%, Passenger Flight Profit increased by $1.0 million or 10%, with Flight Margin at 15.2% versus 19.7% in the prior year period.
Medical Flight Profit increased by $11.1 million or 96% for the year ended December 31, 2023, from $11.6 million in the same period of 2022 to $22.7 million in 2023. The increase was attributable primarily to increased revenue from new and existing clients and an increase in average flight hours per trip.
MediMobility Organ Transport revenue increased by $56.8 million or 380% from $15.0 million in 2021 to $71.8 million in 2022.
Short Distance revenue increased by $25.7 million or 57% from $45.0 million in 2022 to $70.7 million in 2023.